A case of endometrial carcinoma progressed during pregnancy resulting in fetal death.
Endometrial carcinoma
Fetal death
Pregnancy
Progesterone
Journal
International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
08
04
2020
accepted:
06
05
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
Most endometrial carcinomas (ECs) occurring during pregnancy are diagnosed in the first trimester. During the gestation period, progesterone level, which has a protective effect on the endometrium, is found to increase. In EC cases, administering high-dose progesterone is a therapeutic strategy because this hormone can considerably shrink tumors. Herein, the case of a woman in whom EC progressed during pregnancy is reported. Before pregnancy, she was diagnosed with atypical polypoid adenomyoma based on a blind office biopsy. She spontaneously conceived 2 months later, although she was suggested to undergo dilatation and curettage under general anesthesia to confirm the diagnosis. Subsequently, fetal death occurred at 26 weeks. A vaginal delivery was deemed impossible due to vaginal metastasis of EC; thus, cesarean section was performed. Computed tomography revealed multiple lung, pelvic, and inguinal lymph node metastases. Additional biopsy demonstrated poorly differentiated endometrioid carcinoma. She underwent systemic chemotherapy. However, eventually, the disease progressed, resulting in death 11 months after the cesarean section. In the present case, grade 3 EC may have existed before pregnancy, and this condition could have been diagnosed if hysteroscopic resection or total curettage under general anesthesia was performed. Grade 1 tumor may have been eliminated by the high progesterone level maintained during pregnancy, and thus, only grade 3 tumor progressed. Women who wish to preserve their fertility should undergo precise whole endometrial examination. If not, the fetus and mother may consequently experience an eventful clinical course.
Identifiants
pubmed: 32582523
doi: 10.1007/s13691-020-00417-3
pii: 417
pmc: PMC7297887
doi:
Types de publication
Case Reports
Langues
eng
Pagination
159-161Informations de copyright
© The Japan Society of Clinical Oncology 2020.
Déclaration de conflit d'intérêts
Conflict of interestThere are no disclosures for this manuscript.
Références
Obstet Gynecol. 1984 Sep;64(3):417-20
pubmed: 6462572
Arch Gynecol Obstet. 2016 Jan;293(1):177-181
pubmed: 26209972
Am J Obstet Gynecol. 2003 Oct;189(4):1128-35
pubmed: 14586366
Obstet Gynecol. 1964 Dec;24:857-64
pubmed: 14244866
Arch Gynecol Obstet. 2012 Jan;285(1):195-205
pubmed: 21858441
Oncologist. 2002;7(4):279-87
pubmed: 12185292
J Obstet Gynaecol Res. 2000 Dec;26(6):417-20
pubmed: 11152326
Gynecol Oncol Rep. 2019 Mar 27;28:101-103
pubmed: 30993161
Surg Oncol. 2011 Dec;20(4):e175-85
pubmed: 21733678
Am J Obstet Gynecol. 2014 Jul;211(1):7-14
pubmed: 24316272
Eur J Obstet Gynecol Reprod Biol. 2019 May;236:14-21
pubmed: 30875539
Obstet Gynecol. 1981 Jun;57(6):699-704
pubmed: 7015203